StreetInsider.com News Articles

Defence Therapeutics Announces Convertible Debenture Interest Payment

Fri, 23 Oct 2026 16:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company.

The Company announces that, in accordance with the terms and conditions of convertible debentures dated September 15, 2025, representing a principal amount of $2,000,000 and bearing interest at a rate of 8% per annum (the "Debentures"), the Company issued 320,000 common shares in the share capital of the Company (the

Defence Therapeutics Announces Convertible Debenture Interest Payment

Fri, 23 Oct 2026 16:15:00 -0400

Defence Therapeutics Announces Convertible Debenture Interest Payment

Fri, 23 Oct 2026 16:15:00 -0400

Defence Therapeutics Announces Convertible Debenture Interest Payment

Fri, 23 Oct 2026 16:15:00 -0400

Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform

Mon, 19 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum^®-ADC research and leading a main-stage discussion alongside internationally recognized experts in antibody-drug conjugates ("ADCs").

These achievements highlight the growing recognition of Defence's Accum^® technology within the global ADC community. World ADC is a leading international scientific conference bringing together

Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform

Mon, 19 Oct 2026 03:15:00 -0400

These achievements highlight the growing recognition of Defence's Accum^® technology within the global ADC community. World ADC is a leading international scientific conference bringing together

Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform

Mon, 19 Oct 2026 03:15:00 -0400

These achievements highlight the growing recognition of Defence's Accum^® technology within the global ADC community. World ADC is a leading international scientific conference bringing together

Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform

Mon, 19 Oct 2026 03:15:00 -0400

These achievements highlight the growing recognition of Defence's Accum^® technology within the global ADC community. World ADC is a leading international scientific conference bringing together

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.

World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.

Defence to

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.
World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.
Defence to

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.
World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.
Defence to

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

Thu, 01 Oct 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to announce its participation in the 17^th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California.
World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.
Defence to

Defence Therapeutics names ex-Xenon CFO Sherry Aulin to its board

Tue, 29 Sep 2026 03:16:11 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.

Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.

Earlier in her career, Aulin held senior roles at KPMG

Defence Therapeutics names ex-Xenon CFO Sherry Aulin to its board

Tue, 29 Sep 2026 03:16:11 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.

Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.

Earlier in her career, Aulin held senior roles at KPMG

Defence Therapeutics names ex-Xenon CFO Sherry Aulin to its board

Tue, 29 Sep 2026 03:16:11 -0400

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has appointed Sherry Aulin to its board of directors, the Montreal-based biotechnology company announced. Aulin will also serve on the company's audit committee.

Aulin has more than 20 years of experience in public-company finance and capital markets. She most recently served as chief financial officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, for over a decade. During her tenure at Xenon, she contributed to the company's Nasdaq IPO and led financing activities that raised more than $1 billion in equity capital.

Earlier in her career, Aulin held senior roles at KPMG

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Tue, 29 Sep 2026 03:15:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.
Sherry Aulin is a finance executive with more than 20 years of experience working with public companies and in the capital markets. She was most recently Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company,

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")

Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities

Mon, 28 Sep 2026 17:00:00 -0400

Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum^® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders.
Since assuming the role of President and Chief Executive Officer in August, Dr. Amie Phinney and the Defence leadership team have focused on translating the Company's strategy into execution across its scientific programs, leadership and operations. Defence is prioritizing Accum^®-enhanced antibody-drug conjugate ("ADC")